Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212
J. Clin. Invest. J. Ludovic Croxford, et al. 111:1231 doi:10.1172/JCI17652 [Go to this article.]

Figure 1
Cannabinoid receptor agonism ameliorates the clinical severity of established TMEV-induced demyelinating disease. Treatment with R(+)WIN55,212 (filled circles) inhibits TMEV-induced clinical disease when administered, at the time of infection (a), at the onset of clinical disease (b), or during established disease (c). Rx, duration of administration of WIN55,212 to mice. *Significant inhibition (P < 0.05) of clinical disease score in R(+)WIN55,212-treated mice compared with S(–)WIN55,212 (open circles) or untreated TMEV mice (filled triangles). Data are representative of three separate experiments.